Vigil Neuroscience Inc. (VIGL)
2.29
-0.13 (-5.37%)
At close: Mar 03, 2025, 12:15 PM
No 1D chart data available
| Bid | 2.27 |
| Market Cap | 93.41M |
| Revenue (ttm) | 1.95M |
| Net Income (ttm) | -83.21M |
| EPS (ttm) | -2.07 |
| PE Ratio (ttm) | -1.1 |
| Forward PE | -1.06 |
| Analyst | Buy |
| Ask | 2.3 |
| Volume | 58,787 |
| Avg. Volume (20D) | 1,138,455 |
| Open | 2.50 |
| Previous Close | 2.42 |
| Day's Range | 2.26 - 2.50 |
| 52-Week Range | 1.49 - 6.06 |
| Beta | 1.85 |
About VIGL
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy wi...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 7, 2022
Employees 66
Stock Exchange NASDAQ
Ticker Symbol VIGL
Website https://www.vigilneuro.com
Analyst Forecast
According to 5 analyst ratings, the average rating for VIGL stock is "Buy." The 12-month stock price forecast is $22, which is an increase of 862.80% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago
+15.76%
Vigil Neuroscience shares are trading higher after...
Unlock content with
Pro Subscription
7 months ago
-10.02%
Vigil Neuroscience shares are trading lower. The company announced an update following a Type C Meeting with the U.S. Food and Drug Administration to its clinical development strategy for its IGNITE clinical trial evaluating iluzanebart in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.
